InvestorsHub Logo
Followers 7
Posts 299
Boards Moderated 0
Alias Born 01/07/2010

Re: Mikesc post# 117092

Thursday, 08/24/2017 5:14:34 PM

Thursday, August 24, 2017 5:14:34 PM

Post# of 469993
Thanks for sharing, Mike. My guess is Anavex follows this trial design path. Looks like the measures are subjective/caregiver-assessed and wondering if any trial biomarkers exist/been used in the past or gleaned from AVXL's genetic testing in AZ.
Avg. 16% progressive improvement in 6 weeks is the benchmark to keep in mind.
A future P3 of A2-73 should include an arm of A2-73+trofinetide. Neuren is pretty broke and Anavex could buy it if found useful.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News